Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 1:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 756 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Raised Intraocular Pressure Clear all
Completed No phase listed Observational Accepts healthy volunteers

Tracking Optical Coherence Tomography

NCT00343603
View directory record Official record
Conditions
Macular Degeneration, Glaucoma, Diabetic Retinopathy, Choroidal Disease
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2011
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 25, 2016 · Synced Nov 13, 2026, 1:13 AM EST
Completed Phase 3 Interventional Results available

Safety and Efficacy of T-2345 Compared to Xalatan in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

NCT02059278
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Ocular Hypertension
Interventions
T-2345, Xalatan
Drug
Lead sponsor
Nephron Pharmaceuticals Corporation
Industry
Eligibility
18 Years and older
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Aug 22, 2018 · Synced Nov 13, 2026, 1:13 AM EST
Active, not recruiting Not applicable Interventional

Electrical Stimulation for the Treatment of Optic Neuropathies

NCT05626426
View directory record Official record
Conditions
Glaucoma, Glaucoma, Open-Angle, Optic Nerve Diseases
Interventions
Repetitive, Transorbital Alternating Current Stimulation (rtACS)
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 13, 2026, 1:13 AM EST
Completed Phase 4 Interventional Results available

A Comparison of Azopt Versus Placebo Added to Xalatan in Patients With Elevated Intraocular Pressure (IOP) on a Prostaglandin

NCT00759941
View directory record Official record
Conditions
Glaucoma
Interventions
Brinzolamide 1% ophthalmic solution (Azopt), Placebo eye drops, Latanoprost 0.005% ophthalmic solution (Xalatan)
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
35 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2014 · Synced Nov 13, 2026, 1:13 AM EST
Completed Not applicable Interventional Results available

Comparison of Ex-PRESSTM Mini Glaucoma Shunt to Trabeculectomy in Subjects With Open Angle Glaucoma

NCT00444080
View directory record Official record
Conditions
Glaucoma
Interventions
Trabeculectomy, Ex-PRESS mini shunt
Procedure · Device
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 100 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
7
States / cities
San Francisco, California • Gainesville, Florida • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2020 · Synced Nov 13, 2026, 1:13 AM EST
Not yet recruiting Phase 4 Interventional

Iopidine to Decrease Intraocular Pressure Rise After Injections

NCT07891910
View directory record Official record
Conditions
Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusion, Glaucoma
Interventions
Apraclonidine 1.0% ophthalmic solution
Drug
Lead sponsor
Retina Consultants of Delmarva
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Easton, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 13, 2026, 1:13 AM EST
Recruiting Phase 4 Interventional Accepts healthy volunteers

Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma

NCT07209410
View directory record Official record
Conditions
Glaucoma
Interventions
Brimonidine Tartrate Ophthalmic 0.025%
Drug
Lead sponsor
Insight Eyecare Specialties, Inc. dba Vision Source Eyecare,
Other
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Nov 13, 2026, 1:13 AM EST
Completed Phase 2 Interventional

AR-12286 in Combination With Latanoprost

NCT01302249
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Latanoprost 0.005%, AR-12286 Ophthalmic Solution 0.5%, Timolol maleate ophthalmic solution 0.5%
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
15
States / cities
New Haven, Connecticut • Roswell, Georgia • Shawnee Mission, Kansas + 11 more
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Nov 13, 2026, 1:13 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Providing Financial Incentives to Improve Adherence to Referral Eye Care Visits

NCT04328207
View directory record Official record
Conditions
Glaucoma, Diabetic Retinopathy, Refractive Errors, Cataract, Behavior, Health
Interventions
No Financial Incentive, Financial Incentive
Other · Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Nov 13, 2026, 1:13 AM EST
Completed Phase 4 Interventional Results available

SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA)

NCT02419508
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension, Brinz/brim vehicle, Prostaglandin analogue
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Nov 13, 2026, 1:13 AM EST
Terminated No phase listed Observational Accepts healthy volunteers

Intraocular Pressure (IOP) Changes Associated With Muslim Prayer Postural Changes

NCT00454025
View directory record Official record
Conditions
Glaucoma
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 30, 2013 · Synced Nov 13, 2026, 1:13 AM EST
Recruiting Phase 3 Interventional

Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

NCT07495852
View directory record Official record
Conditions
Glaucoma
Interventions
Gen 2 Travoprost Intracameral Implant, Timolol eye drops 0.5%, Sham Procedure, placebo eye drops
Drug · Procedure · Other
Lead sponsor
Glaukos Corporation
Industry
Eligibility
18 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Dothan, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Nov 13, 2026, 1:13 AM EST
Not listed Not applicable Interventional

Multicenter Post-Approval Study Of The Glaukos® iStent® Trabecular Micro-Bypass Stent System In Conjunction With Cataract Surgery

NCT01841450
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
iStent, Cataract surgery
Device · Procedure
Lead sponsor
Glaukos Corporation
Industry
Eligibility
22 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
14
States / cities
Irvine, California • Montebello, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2021 · Synced Nov 13, 2026, 1:13 AM EST
Completed Phase 3 Interventional Results available

Evaluation of Safety of SPARC0913 in Open Angle Glaucoma or Ocular Hypertension

NCT00945958
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
SPARC0913
Drug
Lead sponsor
Sun Pharma Advanced Research Company Limited
Industry
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Nov 13, 2026, 1:13 AM EST
Completed Phase 3 Interventional Results available

A Long-term Safety Study of Once-daily Travatan

NCT00051168
View directory record Official record
Conditions
Glaucoma, Open-angle, Ocular Hypertension
Interventions
Travatan
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2011 · Synced Nov 13, 2026, 1:13 AM EST
Enrolling by invitation No phase listed Observational

5-Year Postoperative Outcomes of Patients Who Completed the CREST Study

NCT07480343
View directory record Official record
Conditions
Open-angle Glaucoma (OAG)
Interventions
CycloPen Micro-Interventional Cyclodialysis System, CycloPen Micro-Interventional Cyclodialysis System Post Cataract
Procedure
Lead sponsor
Iantrek, Inc.
Industry
Eligibility
Not listed
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
10
States / cities
Newport Beach, California • Cape Coral, Florida • DeLand, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Nov 13, 2026, 1:13 AM EST
Terminated No phase listed Observational Accepts healthy volunteers

Optical Coherence Tomography (OCT) Reference Data Collection Study (S-2015-3)

NCT02785042
View directory record Official record
Conditions
Glaucoma
Interventions
Heidelberg Spectralis OCT
Device
Lead sponsor
Heidelberg Engineering GmbH
Industry
Eligibility
18 Years to 90 Years
Enrollment
224 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2023
U.S. locations
8
States / cities
La Jolla, California • Santa Monica, California • Santa Rosa, California + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Nov 13, 2026, 1:13 AM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparison of Combigan Two Times Daily (BID) Versus Simbrinza Three Times Daily (TID)

NCT02167035
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Combigan Two Times Daily (BID), Simbrinza Three Times Daily (TID)
Drug
Lead sponsor
Cornerstone Health Care, PA
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Nov 13, 2026, 1:13 AM EST
Completed Phase 2 Interventional Results available

Study of Fixed-Dose Combinations of Trabodenoson and Latanoprost in Adults With OHT or POAG

NCT02829996
View directory record Official record
Conditions
Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Interventions
trabodenoson 6.0% / latanoprost 0.005% QD, trabodenoson 3.0% / latanoprost 0.005% QD, trabodenoson 6.0% / latanoprost 0.0025% QD, latanoprost 0.005% QD, latanoprost 0.0025% QD
Drug
Lead sponsor
Inotek Pharmaceuticals Corporation
Industry
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 15, 2018 · Synced Nov 13, 2026, 1:13 AM EST
Active, not recruiting Phase 2 Interventional

Study of NT-501 Encapsulated Cell Therapy for Glaucoma Neuroprotection and Vision Restoration

NCT02862938
View directory record Official record
Conditions
Glaucoma
Interventions
NT-501 ECT implant, Sham
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Nov 13, 2026, 1:13 AM EST
Completed Phase 1Phase 2 Interventional

A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHT

NCT01654484
View directory record Official record
Conditions
Glaucoma and Ocular Hypertension
Interventions
DE-117, 0.0015% tafluprost, DE-117 and 0.0015% tafluprost, Placebo
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
10
States / cities
Newport Beach, California • Deerfield Beach, Florida • Largo, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2018 · Synced Nov 13, 2026, 1:13 AM EST
Withdrawn Not applicable Interventional Accepts healthy volunteers

Eye Health Intervention Study in Upper Manhattan

NCT06112431
View directory record Official record
Conditions
Glaucoma, Suspect, Diabetic Retinopathy, Cataract, Refractive Errors, Vision Impairment and Blindness
Interventions
Intervention, Usual Care
Other
Lead sponsor
Columbia University
Other
Eligibility
40 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2031
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Nov 13, 2026, 1:13 AM EST
Completed Not applicable Interventional

NIDEK Gonioscope GS-1 for Glaucoma

NCT03715231
View directory record Official record
Conditions
Glaucoma
Interventions
NIDEK Gonioscope GS-1, Standard Digital Gonioscopic Images
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 30, 2021 · Synced Nov 13, 2026, 1:13 AM EST
Completed No phase listed Observational

Survey of Patients Taking IOP-Lowering Eye Drops

NCT02384772
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Survey
Other
Lead sponsor
ForSight Vision5, Inc.
Industry
Eligibility
Not listed
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Menlo Park, California
Source: ClinicalTrials.gov public record
Updated Jun 11, 2015 · Synced Nov 13, 2026, 1:13 AM EST